Navigation Links
OncoGenex Pharmaceuticals CEO Named Canada's Pacific Ernst & Young's Entrepreneur Of The Year(R) in the Health Sciences Category
Date:10/9/2009

BOTHELL, WA, and VANCOUVER, Oct. 9 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), announced today that Scott Cormack, president and chief executive officer of OncoGenex, has been named Canada's Pacific Ernst & Young's Entrepreneur Of The Year(R). The Ernst & Young Entrepreneur Of The Year(R) Award is a high profile business award recognizing entrepreneurs that are building successful, dynamic businesses.

"I share this award with our co-founder Dr. Martin Gleave and all of our employees at OncoGenex, whose contributions and exceptional dedication to our programs have led to a series of major clinical and business advancements over the past 12 months," said Scott Cormack, President and CEO of OncoGenex.

"Over the past year, we have presented impressive data from the clinical trials of our lead drug candidate, OGX-011, for the treatment of advanced prostate cancer; reached agreements with the FDA on the design of two Phase 3 trials for evaluating OGX-011 treatment in advanced prostate cancer via the FDA's special protocol assessment process; received Fast Track designations from FDA for OGX-011 in combination with both first-line and second-line chemotherapy in advanced prostate cancer, which are expected to streamline the regulatory review process; presented data from our Phase 1 clinical trial evaluating our second product candidate, OGX-427; and initiated another clinical trial with OGX-427 in bladder cancer," Cormack said.

"For the remaining 2009 year, we are committed to securing a partner to support the final stage of development of OGX-011 and announcing additional development initiatives for our other product candidates."

Ernst & Young's Entrepreneur Of The Year(R) Award encourages entrepreneurial activity among those with potential and recognizes the contribution
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2013 was a banner year of continued ... saw continued independent research led by the team at ... $1 million grant from the Susanne Marcus Collins Foundation, ... peer reviewed journal, Amy Grant highlighted Brainwave Optimization® in ...
(Date:1/14/2014)... Carahsoft and CDS Federal Services have scheduled a ... EST (11am PST), “Natural Language Processing: Converting Raw Data ... can turn raw, heterogeneous data into actionable knowledge to ... webinar will last approximately one hour. , Synopsis: Big ...
(Date:1/14/2014)... 2014 The largest international professional organization of ... therapeutic derivatives thereof has endorsed an educational program ... the challenges of adulterated herb and botanical products. ... The Society for Medicinal Plant and Natural ...
(Date:1/14/2014)... Global Record Systems, LLC, (GRS), a ... for patients, physicians, the biopharmaceutical industry, regulators, payers, ... signing of a three-year Research Collaboration Agreement (RCA) ... This initiative is designed to generate disruptive ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... April 20 Quark Pharmaceuticals, Inc., a development-stage ... (RNAi)-based therapeutics, today announced that James D. Thompson, ... presentation on Tuesday, April 20 at this year,s ... Annual Meeting, which is taking place from April ...
... COPENHAGEN, April 20 Santaris Pharma announced ... in vivo activity of microRNA-targeted,therapeutics against cancer ... Locked,Nucleic Acid (LNA) Drug Platform. In both ... cancer targeted LNA-antimiR(R),s demonstrated outstanding,recognition and inhibition ...
... 20 Mpex Pharmaceuticals, Inc. today announced that Mark Wiggins ... Wiggins comes to Mpex from Biogen Idec, Inc. where he ... and was a member of the Executive Committee. At ... development activities related to the company,s lead product, MP-376. ...
Cached Biology Technology:Quark Pharmaceuticals to Present at American Society for Pharmacology and Experimental Therapeutics Annual Meeting 2Quark Pharmaceuticals to Present at American Society for Pharmacology and Experimental Therapeutics Annual Meeting 3LNA-Based RNA oligonucleotides Potently Inhibit Cancer microRNAs 2Mpex Pharmaceuticals Names Mark Wiggins Chief Business Officer 2Mpex Pharmaceuticals Names Mark Wiggins Chief Business Officer 3
(Date:4/18/2014)... a twist to the story of how barnyard chickens came ... in the journal Proceedings of the National Academy of ... that lived 200-2300 years ago in Europe, researchers report that ... looked far different from the chickens we know today. , ... with modern domestic chickens -- such as their yellowish skin ...
(Date:4/18/2014)... [Brown University] Asteroid and comet impacts can cause ... regional or even global scales. But new research from ... signatures of ancient life at the time of an ... Pete Schultz has found fragments of leaves and preserved ... ancient impacts in Argentina. The material could provide a ...
(Date:4/17/2014)... the most densely forested and most densely populated quadrant ... human needs, values and practices. Disturbances associated with those ... and development, have set the stage for management issues ... reports. , The report Five anthropogenic factors that ... the Northern United States was published recently ...
Breaking Biology News(10 mins):Ancient DNA offers clues to how barnyard chickens came to be 2Impact glass stores biodata for millions of years 2Impact glass stores biodata for millions of years 3Five anthropogenic factors that will radically alter northern forests in 50 years 2Five anthropogenic factors that will radically alter northern forests in 50 years 3
... more corals and fish generate predictably greater levels of ... has important implications for understanding the behaviour of young ... environmental health by listening to reefs. Contrary to ... places, with fish and invertebrates producing clicks and grunts ...
... SALT LAKE CITYResearchers at Huntsman Cancer Institute (HCI) at the ... necessary for the maintenance and repair of the cell,s cytoskeleton, ... of the cell. The research has implications for cancer, as ... often associated with disease. The research was published in the ...
... failure of the Deepwater Horizon oil well last spring, nearly ... of Mexico to contain the spill. While preliminary reports suggest ... effect of such a massive volume of dispersant on ecosystems, ... a University at Buffalo researcher with expertise in how the ...
Cached Biology News:Taking the pulse of coral reefs 2Study offers first explanation of how cells rapidly repair and maintain structure 2A less toxic, more efficient dispersant is scientist's goal 2